Other studies have also found that DZXXI can reduce the blood lipid level of patients with angina pectoris, improve lipid metabolism, reduce the expression levels of IL-6, CRP and TNF-α in the serum of patients, improve inflammation, and inhibit the development of angina pectoris (Zhao et al. (2008); Li and Yang, 2014). The gene discussed is CRP; the disease is angina pectoris.